Company Overview of H. Lee Moffitt Cancer Center & Research Institute
H. Lee Moffitt Cancer Center & Research Institute is a not for-profit institution that focuses on prevention and cure of cancer. The institution offers private patient rooms, blood and marrow transplant programs, outpatient treatment programs, patient care, research, and education services. Additionally, it publishes Today's Tomorrows, a community newsletter about cancer care, research, and education. H. Lee Moffitt was founded in 1986 and is based in Tampa, Florida.
10441 University Center Drive
Tampa, FL 33612
Founded in 1986
Key Executives for H. Lee Moffitt Cancer Center & Research Institute
Chief Executive Officer and Center Director
Executive Vice President Applied Science
Vice President of Public Relations and Marketing
Compensation as of Fiscal Year 2015.
H. Lee Moffitt Cancer Center & Research Institute Key Developments
Cancer Genetics, Inc. Enters into Multi-Year Research Collaboration with Moffitt Cancer Center for Genomics-Based Prediction of Side Effects Associated with Chemotherapy
May 6 15
Cancer Genetics, Inc. announced that it has entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center in Tampa, Florida. The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, Howard McLeod, PharmD, and Gillian Bell, PharmD will examine a number of genetic variants as predictors for the most common side effects associated with chemotherapy treatment. Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical challenge experienced by over 50% of patients receiving chemotherapy, even when general-purpose prophylactic anti-emetic therapies are prescribed according to clinical guidelines. The first of these collaborative studies will seek to validate and improve existing risk prediction indices of acute and delayed CINV in patients undergoing chemotherapy. This prospective study will determine whether the inclusion of variations in genes involved in the metabolism of anti-emetic drugs improves the ability to accurately predict which patients are more likely to experience side effects from chemotherapy regimens. Tailored anti-emetic treatment in patients at risk of CINV has the potential to significantly reduce incidence, while decreasing CINV-related medical visit costs, which average $40,001 per patient. A second collaboration will examine the role of individual genetic variants in the effectiveness of pain control in cancer. Pain is one of the most difficult symptoms associated with cancer and its treatment. Opioid and non-opioid analgesics and co-analgesics are frequently used to improve pain control, but patients vary considerably in their response to these drugs. This study will include Moffitt cancer patients treated in the outpatient setting and will seek to identify genetic associations for patient-reported pain outcomes.
H. Lee Moffitt Cancer Center Names Mariana Bugallo-Muros as Chief Human Resources Officer
May 5 15
H. Lee Moffitt Cancer Center named a new Lead Executive for the Human Resources Department. Mariana Bugallo-Muros will be Chief Human Resources Officer for the Tampa-based center, filling the role left vacant by Joanne Olson, who retired in March. Bugallo-Muros, who is expected to start at Moffitt in June, previously was vice president for Partners HealthCare in Boston.
Moffitt Cancer Center Names Jennifer Greenman to Vice President and Chief Information Officer
Dec 4 14
Jennifer Greenman has been named Vice President and Chief Information Officer at Moffitt Cancer Center. She will report to Mark Hulse, R.N., Moffitt's Chief Administration Officer. In her new role, Greenman will provide leadership and strategic direction for technology initiatives that support Moffitt's mission to contribute to the prevention and cure of cancer. Greenman has been with Moffitt since July 2013. She previously served as the cancer center's Senior Director for Application Services.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|